Niteks on Novo Nordisk nudnud, et Texase, Florida, New Yorgi osariigi ja Tennessee kehakaalu alandamise ja tervisekliinikud lpetaksid valereklaami ja avaldaksid, et nende tooted ei ole Novo Nordiskiga seotud
Retatrutide is currently undergoing phase 3 trials and we expect it to be available as a prescription medication in 2029
Eden's semaglutide works through the same mechanism as other GLP-1 receptor agonists, potentially affecting both weight management and metabolic functions
While clinical studies have shown no clinically relevant effect on the absorption of oral medications, monitoring of INR is advised for patients taking warfarin or other coumarin anticoagulants
Drugmaker Eli Lilly announced that the FDA approved its daily GLP-1 pill, which will be marketed under the name Foundayo, to treat obesity
Clean with an alcohol pad